Atrium Therapeutics(RNA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

RNA Atrium Therapeutics

已收盘 05-05 16:00:00 EDT

12.91

+0.04

+0.31%

盘后12.91

+0.000.00%

18:41 EDT

最高13.04	最低12.75	成交量32.10万
今开12.93	昨收12.87	日振幅2.25%
总市值2.00亿	流通市值1.44亿	总股本1,552万
成交额415.45万	换手率2.88%	流通股本1,114万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"RNA","market":"US","secType":"STK","nameCN":"Atrium Therapeutics","latestPrice":12.91,"timestamp":1778011200000,"preClose":12.87,"halted":0,"volume":320990,"hourTrading":{"tag":"盘后","latestPrice":12.91,"preClose":12.91,"latestTime":"18:41 EDT","volume":218404,"amount":2819594.54,"timestamp":1778020865609,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.00310800310800318,"floatShares":11135300,"shares":15515000,"eps":-3.191,"marketStatus":"已收盘","change":0.04,"latestTime":"05-05 16:00:00 EDT","open":12.93,"high":13.04,"low":12.75,"amount":4154516.11279,"amplitude":0.022533,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.191,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1778054400000},"marketStatusCode":5,"adr":0,"listingDate":1591934400000,"exchange":"NASDAQ","adjPreClose":12.87,"preHourTrading":{"tag":"盘前","latestPrice":12.93,"preClose":12.87,"latestTime":"09:29 EDT","volume":2121,"amount":27486.371997,"timestamp":1777987770125,"change":0.06,"changeRate":0.004662,"amplitude":0.0777},"postHourTrading":{"tag":"盘后","latestPrice":12.91,"preClose":12.91,"latestTime":"18:41 EDT","volume":218404,"amount":2819594.54,"timestamp":1778020865609,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.358909,"impliedVol":0.1535,"impliedVolPercentile":0.1225},"requestUrl":"/m/hq/s/RNA/tweets","defaultTab":"tweets","newsList":[{"id":"2630932874","title":"【券商聚焦】方正证券维持云顶新耀(01952)“强烈推荐”评级 指RNA平台进一步验证","url":"https://stock-news.laohu8.com/highlight/detail?id=2630932874","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630932874?lang=zh_cn&edition=full","pubTime":"2026-04-28 11:09","pubTimestamp":1777345757,"startTime":"0","endTime":"0","summary":"金吾财讯 | 方正证券发布研报指，云顶新耀 在AACR大会发布mRNA肿瘤疫苗EVM16首次人体数据，RNA平台进一步验证。商业化成果显著，2025年公司实现收入17.07亿元人民币，大幅增长141.51%。截至2025年12月31日，公司现金储备达27.31亿元人民币。盈利预测方面，方正证券预计2026-2028年公司销售收入分别为39.56/54.52/71.41亿元人民币，同比增长131.78%/37.83%/30.98%；归母净利润分别为2.53/6.65/11.47亿元人民币，维持“强烈推荐”评级。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1980112","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["601901","RNA","01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105218816","title":"Atrium Therapeutics获施贵宝心血管合作1500万美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1105218816","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105218816?lang=zh_cn&edition=full","pubTime":"2026-04-23 20:04","pubTimestamp":1776945856,"startTime":"0","endTime":"0","summary":"Atrium Therapeutics宣布，根据其与施贵宝达成的全球心血管领域合作协议，公司已成功获得一笔1500万美元的里程碑付款。此次付款标志着双方合作取得了重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","IE00BSNM7G36.USD","LU1868836591.USD","LU1291159041.SGD","BK4532","BK4585","IE00BJJMRZ35.SGD","LU1093756325.SGD","LU1868837136.USD","RNA","LU1323610961.USD","LU1571399168.USD","BK4139","LU0061475181.USD","BK4581","IE0009355771.USD","IE00BFTCPJ56.SGD","LU2360032135.SGD","BK4588","BMY","BK4505","LU0114720955.EUR","IE00B2B36J28.USD","LU0096364046.USD","LU1093756168.USD","LU0432979614.USD","LU1868836914.USD","LU1032466523.USD","LU0225771236.USD","LU1883839398.USD","LU2125154778.USD","IE0009354923.USD","BK4007","LU1868836757.USD","LU0882574055.USD","LU0321505439.SGD","LU0237698245.USD","LU1074936037.SGD","LU0267386448.USD","IE00BJT1NW94.SGD","BK4559","LU0306806265.USD","LU0306807586.USD","LU0456855351.SGD","LU1670710661.SGD","LU1868837300.USD","LU1585245621.USD","BK4534","LU0321505868.SGD","LU1718418525.SGD","LU2133065610.SGD","LU0225284248.USD","LU0868494617.USD","LU0985481810.HKD","LU1989771016.USD","LU2242646821.SGD","IE00BFXG1179.USD","LU2242652126.USD","LU1670710588.SGD","LU1670711040.USD","LU1670711123.USD","LU1261432733.SGD","LU1983299246.USD","LU1430594728.SGD","LU2125154935.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181426981","title":"施贵宝将全面资助Atrium Therapeutics合作项目未来所有临床、注册及商业化活动","url":"https://stock-news.laohu8.com/highlight/detail?id=1181426981","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181426981?lang=zh_cn&edition=full","pubTime":"2026-04-23 20:03","pubTimestamp":1776945801,"startTime":"0","endTime":"0","summary":"根据最新合作协议条款，施贵宝（Bristol Myers Squibb）将承担与Atrium Therapeutics合作项目后续所有临床开发、注册申报及商业化活动的全部资金。这一安排标志着双方战略合作进入新阶段，由施贵宝主导推进项目全球化进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868836591.USD","LU1670710588.SGD","IE00BJJMRZ35.SGD","IE0009354923.USD","LU0306806265.USD","LU0985481810.HKD","LU2242646821.SGD","LU1868837300.USD","LU0432979614.USD","LU2133065610.SGD","IE00BFXG1179.USD","LU1074936037.SGD","LU1989771016.USD","LU1093756168.USD","BMY","LU1093756325.SGD","LU1868836914.USD","LU0267386448.USD","LU1883839398.USD","LU2125154935.USD","BK4559","IE0002141913.USD","LU1868836757.USD","IE00BFTCPJ56.SGD","LU0096364046.USD","LU1323610961.USD","LU1261432733.SGD","BK4585","LU1718418525.SGD","LU2242652126.USD","LU1670711040.USD","IE00BJT1NW94.SGD","BK4581","LU2125154778.USD","LU0456855351.SGD","LU0114720955.EUR","LU0868494617.USD","LU0225284248.USD","LU1670711123.USD","LU0061475181.USD","BK4532","LU1032466523.USD","BK4007","LU0882574055.USD","LU1430594728.SGD","LU0306807586.USD","LU0225771236.USD","IE00BSNM7G36.USD","LU0237698245.USD","LU1291159041.SGD","LU1983299246.USD","LU2360032135.SGD","BK4139","RNA","BK4505","LU1670710661.SGD","LU1585245621.USD","LU0321505868.SGD","LU1571399168.USD","LU1868837136.USD","BK4588","IE0009355771.USD","LU0321505439.SGD","BK4534","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123489677","title":"Atrium Therapeutics 有望获得高达13.5亿美元研发里程碑付款、8.25亿美元商业里程碑付款及分层特许权使用费","url":"https://stock-news.laohu8.com/highlight/detail?id=1123489677","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123489677?lang=zh_cn&edition=full","pubTime":"2026-04-23 20:02","pubTimestamp":1776945720,"startTime":"0","endTime":"0","summary":"生物技术公司Atrium Therapeutics Inc（RNA）宣布，其与制药巨头施贵宝（BMY）达成的合作协议中，包含丰厚的潜在财务回报。根据协议条款，Atrium有资格获得最高可达13.5亿美元的研发里程碑付款。\n此外，协议还涵盖了商业成功方面的激励。该公司有望进一步获得高达8.25亿美元的基于销售额的商业里程碑付款。除了这些一次性付款，合作协议还规定Atrium将获得基于产品净销售额的分层特许权使用费。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1323610961.USD","IE00BJT1NW94.SGD","BMY","LU0061475181.USD","IE00BFTCPJ56.SGD","LU0237698245.USD","LU1670710588.SGD","RNA","LU1983299246.USD","LU0114720955.EUR","LU1430594728.SGD","BK4505","LU0306807586.USD","LU1585245621.USD","IE00BFXG1179.USD","LU1670711040.USD","LU1868837300.USD","LU0321505439.SGD","LU0432979614.USD","BK4139","BK4007","BK4534","LU0225771236.USD","IE00B2B36J28.USD","LU0882574055.USD","LU0096364046.USD","LU1074936037.SGD","IE0002141913.USD","LU1093756325.SGD","IE0009355771.USD","BK4588","LU1868836757.USD","IE00BJJMRZ35.SGD","LU1093756168.USD","LU1868836591.USD","LU2125154935.USD","BK4559","IE0009354923.USD","LU2242652126.USD","LU2125154778.USD","IE00BSNM7G36.USD","LU0306806265.USD","LU1261432733.SGD","LU1868836914.USD","LU1670710661.SGD","LU0985481810.HKD","LU2242646821.SGD","LU2360032135.SGD","LU1291159041.SGD","LU1670711123.USD","LU0321505868.SGD","LU0267386448.USD","LU2133065610.SGD","LU0868494617.USD","BK4585","LU1868837136.USD","LU1571399168.USD","LU1718418525.SGD","LU0456855351.SGD","LU1883839398.USD","LU1989771016.USD","LU1032466523.USD","BK4581","BK4532","LU0225284248.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614834631","title":"Wave Life Sciences Ltd.盘中异动 大幅上涨5.09%报15.28美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614834631","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614834631?lang=zh_cn&edition=full","pubTime":"2026-02-27 03:16","pubTimestamp":1772133396,"startTime":"0","endTime":"0","summary":"北京时间2026年02月27日03时16分，Wave Life Sciences Ltd.股票出现波动，股价急速上涨5.09%。截至发稿，该股报15.28美元/股，成交量228.111万股，换手率1.23%，振幅7.29%。Wave Life Sciences Ltd.股票所在的生物技术行业中，整体跌幅为1.98%。Wave Life Sciences Ltd.公司简介：WAVE Life Sciences Ltd 是一家临床阶段的生物技术公司，专注于释放 RNA 药物的广泛潜力，靶向核糖核酸 ，以改变人类健康。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602270316369542259a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602270316369542259a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["WVE","BK4139","BK4505","BK4588","RNA","BK4585","IE0009354923.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137428854","title":"《新英格兰医学杂志》发布Delpacibart Etedesiran治疗1型强直性肌营养不良的MARINA® 1/2期试验结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1137428854","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137428854?lang=zh_cn&edition=full","pubTime":"2026-02-19 06:01","pubTimestamp":1771452074,"startTime":"0","endTime":"0","summary":"《新英格兰医学杂志》近日正式刊载了针对1型强直性肌营养不良治疗的创新疗法Delpacibart Etedesinan（研发代号Del-Desiran）在MARINA® 1/2期临床试验中所取得的研究数据。该试验旨在评估这一候选药物的安全性与初步疗效，为罕见神经肌肉疾病的治疗领域提供了新的科学依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","RNA","IE0009354923.USD","BK4585","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612406701","title":"Wave Life Sciences Ltd.盘中异动 早盘大幅拉升5.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2612406701","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612406701?lang=zh_cn&edition=full","pubTime":"2026-02-18 22:34","pubTimestamp":1771425265,"startTime":"0","endTime":"0","summary":"北京时间2026年02月18日22时34分，Wave Life Sciences Ltd.股票出现异动，股价快速上涨5.72%。Wave Life Sciences Ltd.股票所在的生物技术行业中，整体跌幅为0.45%。Wave Life Sciences Ltd.公司简介：WAVE Life Sciences Ltd 是一家临床阶段的生物技术公司，专注于释放 RNA 药物的广泛潜力，靶向核糖核酸 ，以改变人类健康。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021822342597a675a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021822342597a675a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","WVE","BK4505","SNSE","IE0009354923.USD","RNA","BK4588","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604113059","title":"WAVE Life Sciences：聚焦RNA编辑与RNAi疗法的前沿先锋","url":"https://stock-news.laohu8.com/highlight/detail?id=2604113059","media":"药研前瞻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604113059?lang=zh_cn&edition=full","pubTime":"2026-01-19 15:25","pubTimestamp":1768807551,"startTime":"0","endTime":"0","summary":"其GalNAc-SpiNA siRNA可实现一年一次或两次给药。通过RNA编辑纠正突变有望同时改善肺和肝的病理状态。RestorAATion-2 临床试验正在进行中。400 毫克的 MAD 数据预计将于 2026 年第一季度公布，600 毫克的 SAD 和 MAD 数据预计将于 2026 年公布。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011916052297a25e6e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011916052297a25e6e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4133","BK4585","RNA","WVE","BK4505","BK4539","IE0009354923.USD","BK4588","BK4007","WAVE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603573916","title":"管线成果超预期 获数千万港币里程碑付款！晶泰科技(02228)赋能AI+RNA新药RTX-117获中美临床批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2603573916","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603573916?lang=zh_cn&edition=full","pubTime":"2026-01-14 09:23","pubTimestamp":1768353831,"startTime":"0","endTime":"0","summary":"ReviR 将继续完成 RTX-117 的后续临床开发，晶泰科技有权参与该管线的销售分成及后续授权收益分成。RTX-117 为晶泰科技与 ReviR 深度合作的一系列研发管线中首个里程碑成果，其临床前数据及临床获批速度均超出双方预期。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392536.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK4139","IE0009354923.USD","BK4187","BK4550","LU1929549753.HKD","BK1617","IE00B775SV38.USD","LU0683600562.USD","RNA","LU1280957306.USD","BK4585","LU1162221912.USD","02228","LU1366192091.USD","RTX","IE00B3S45H60.SGD","LU1585245621.USD","LU0640476718.USD","BK4505","LU0320765646.SGD","BK4566","BK1141","LU0787776722.HKD","LU1430594728.SGD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2601723891","title":"Wave Life Sciences Ltd.盘中异动 大幅下跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601723891","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601723891?lang=zh_cn&edition=full","pubTime":"2026-01-05 23:31","pubTimestamp":1767627116,"startTime":"0","endTime":"0","summary":"北京时间2026年01月05日23时31分，Wave Life Sciences Ltd.股票出现异动，股价快速下跌5.02%。截至发稿，该股报15.15美元/股，成交量79.0472万股，换手率0.43%，振幅5.27%。Wave Life Sciences Ltd.股票所在的生物技术行业中，整体跌幅为1.88%。Wave Life Sciences Ltd.公司简介：WAVE Life Sciences Ltd 是一家临床阶段的生物技术公司，专注于释放 RNA 药物的广泛潜力，靶向核糖核酸 ，以改变人类健康。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026010523315697a10ee0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026010523315697a10ee0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4588","WVE","RNA","BK4007","BK4505","BK4139","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2593644938","title":"Wave Life Sciences Ltd.盘中异动 股价大跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593644938","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593644938?lang=zh_cn&edition=full","pubTime":"2025-12-24 03:33","pubTimestamp":1766518412,"startTime":"0","endTime":"0","summary":"北京时间2025年12月24日03时33分，Wave Life Sciences Ltd.股票出现波动，股价急速跳水5.01%。Wave Life Sciences Ltd.股票所在的生物技术行业中，整体涨幅为0.14%。Wave Life Sciences Ltd.公司简介：WAVE Life Sciences Ltd 是一家临床阶段的生物技术公司，专注于释放 RNA 药物的广泛潜力，靶向核糖核酸 ，以改变人类健康。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224033332953b92ee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224033332953b92ee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4588","WVE","RNA","BK4007","BK4505","BK4139","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588701014","title":"Wave Life Sciences Ltd.盘中异动 股价大跌5.03%报7.37美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2588701014","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588701014?lang=zh_cn&edition=full","pubTime":"2025-12-02 04:08","pubTimestamp":1764619730,"startTime":"0","endTime":"0","summary":"北京时间2025年12月02日04时08分，Wave Life Sciences Ltd.股票出现波动，股价快速跳水5.03%。截至发稿，该股报7.37美元/股，成交量97.1002万股，换手率0.58%，振幅3.67%。Wave Life Sciences Ltd.股票所在的生物技术行业中，整体跌幅为1.63%。Wave Life Sciences Ltd.公司简介：WAVE Life Sciences Ltd 是一家临床阶段的生物技术公司，专注于释放 RNA 药物的广泛潜力，靶向核糖核酸 ，以改变人类健康。其项目针对罕见和普遍的疾病，包括 α-1 抗胰蛋白酶缺乏症、肥胖症、杜氏肌营养不良症和亨廷顿病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251202040850a4c6631b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251202040850a4c6631b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","WVE","BK4505","RNA","BK4588","BK4139","BK4585","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586244925","title":"诺华同意收购RNA疗法创新企业Avidity Biosciences，以强化其后期阶段的神经科学管线","url":"https://stock-news.laohu8.com/highlight/detail?id=2586244925","media":"动脉网","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586244925?lang=zh_cn&edition=full","pubTime":"2025-11-25 12:36","pubTimestamp":1764045360,"startTime":"0","endTime":"0","summary":"诺华宣布收购RNA疗法企业Avidity Biosciences，收购将在Avidity分拆早期心脏疾病项目后进行。此次收购契合诺华深耕神经科学的战略，有望填补遗传性疾病治疗空白，扩展公司管线。Avidity项目包含潜在同类首创、处于临床试验后期阶段的疾病修饰疗法，适用于多种罕见神经肌肉疾病。基于诺华专业经验及商业化能力，此次收购有望打造行业领先研发管线，AOC平台将单抗组织特异性与寡核苷酸精准调控结合，有望改变疾病进程，对患者生活产生积极影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251125125311977ddcf7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251125125311977ddcf7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4585","IE00BJT1NW94.SGD","IE0009355771.USD","LU0070302665.USD","IE00B2B36J28.USD","LU0211331839.USD","BK4588","RNA","IE0009354923.USD","BK4578","LU0320765489.SGD","IE00B4R5TH58.HKD","IE0002141913.USD","IE00BFTCPJ56.SGD","BK4139","BK4505","IE00BJJMRZ35.SGD","BK4532","LU0208291251.USD","NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2585632444","title":"石药集团(01093)：双链小干扰RNA药物(SYH2061注射液)在美国获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2585632444","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585632444?lang=zh_cn&edition=full","pubTime":"2025-11-24 18:20","pubTimestamp":1763979613,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，集团自主研发的化学1类新药双链小干扰RNA药物已获得美国食品药品监督管理局批准，可在美国开展临床试验。该产品是一款通过偶联乙酰半乳糖胺实现肝脏靶向递送的siRNA药物，以皮下给药的方式靶向补体蛋白C5，能有效降低C5水平。临床前研究显示，该产品在药物活性和药效持续性方面均优于同类型siRNA产品，展现出药物作用效果持久、安全性良好、患者依从性高等差异化优势，具有较高的临床开发价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1372825.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BZ08YT58.USD","IE0009354923.USD","IE0008368742.USD","LU0880133367.SGD","LU1813983027.USD","LU0067412154.USD","BK1515","LU0326950275.SGD","01093","IE00BZ08YR35.GBP","LU1951186391.HKD","LU1226287529.USD","LU1152091168.USD","LU0072913022.USD","LU1226288170.HKD","LU1993786604.SGD","LU0140636845.USD","BK4585","BK1521","IE00BZ08YS42.EUR","SG9999004220.SGD","LU2039709279.SGD","LU1152091754.HKD","IE00B5MMRT66.SGD","LU1328277881.USD","HK0000165453.HKD","BK1191","RNA","IE0008369823.USD","LU1226287875.USD","LU1807302812.USD","BK4139","LU1226288253.USD","LU0315179316.USD","BK4505","LU0501845795.SGD","IE00B543WZ88.USD","LU1226287792.SGD","LU1960683339.HKD","IE00B031HY20.USD","LU0314109678.HKD","BK4588","LU1008478684.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2585431995","title":"港股异动 | MIRXES-B(02629)早盘涨近8% 携手沃森深耕东盟市场 共建RNA精准医疗创新体系","url":"https://stock-news.laohu8.com/highlight/detail?id=2585431995","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585431995?lang=zh_cn&edition=full","pubTime":"2025-11-24 09:45","pubTimestamp":1763948732,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，MIRXES-B早盘涨近8%，截至发稿，涨2.48%，报53.8港元，成交额1829.42万港元。此次合作标志着精准诊断领军企业与顶尖疫苗研发企业实现战略协同，为构建以RNA为核心的预防及精准医疗平台奠定坚实基础。值得注意的是，今年10月，核心产品GASTROClear经中国国家药品监督管理局批准上市，成为全球首款也是目前唯一获批用于胃癌筛查的分子诊断IVD产品。此次获批意味着公司正式进入中国庞大的胃癌筛查市场，成为短期内最重要的业绩催化剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1372549.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02629","BK1161","BK4585","BK4139","BK4505","IE0009354923.USD","BK4588","RNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2585994111","title":"港股异动 | MIRXES-B(02629)午后涨超5% 携手沃森生物创建以RNA为中心的预防及精准医疗平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2585994111","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585994111?lang=zh_cn&edition=full","pubTime":"2025-11-21 13:43","pubTimestamp":1763703822,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，MIRXES-B午后涨超5%，截至发稿，涨3.44%，报52.55港元，成交额3273.41万港元。消息面上，MIRXES公布，公司近期与云南沃森生物技术订立谅解备忘录，订约方同意就创建以RNA为中心的预防及精准医疗平台建立战略合作伙伴关系，并涵盖共同开发、临床试验及注册以及销售及分销。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1371977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["RNA","300142","BK0077","02629","IE0009354923.USD","BK0239","BK4585","BK4505","BK0046","BK0070","BK4588","BK4139","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140113828","title":"诺华预计2025-2030年销售复合年增长率为+5-6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1140113828","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140113828?lang=zh_cn&edition=full","pubTime":"2025-11-20 14:17","pubTimestamp":1763619458,"startTime":"0","endTime":"0","summary":"11月20日（路透社） - 诺华制药发布消息称，预计2025-2030年的销售复合年增长率将达到+5-6%，长期增长受益于30多项潜在高价值的管线资产。*KISQALI和SCEMBLIX的高峰销售指导上调；诺华目前拥有八项风险降低的市场在售资产，预计高峰销售潜力在30亿至100亿美元之间。*展望：预计到2029年将恢复至40%以上的利润率。*计划收购Avidity Biosciences预计将在2026年上半年完成。*KISQALI的销售指导从80亿美元上调至100亿美元以上；SCEMBLIX的销售指导从30亿美元上调至40亿美元以上。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","IE0009354923.USD","RNA","BK4588","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171191887","title":"Avidity Biosciences宣布美国受管制接入计划（MAP）以用于研究性疗法Del-Zota于Dmd44","url":"https://stock-news.laohu8.com/highlight/detail?id=1171191887","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171191887?lang=zh_cn&edition=full","pubTime":"2025-11-19 22:14","pubTimestamp":1763561655,"startTime":"0","endTime":"0","summary":"Avidity Biosciences宣布美国受管制接入计划（MAP）以用于研究性疗法Del-Zota于Dmd44","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","BK4585","BK4505","IE0009354923.USD","RNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2584891934","title":"佰金生命科学(01466)附属拟入股投资优环生物 打造全球领先的环状RNA(circ RNA)技术研发平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2584891934","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584891934?lang=zh_cn&edition=full","pubTime":"2025-11-19 16:36","pubTimestamp":1763541371,"startTime":"0","endTime":"0","summary":"智通财经APP讯，佰金生命科学 公布，公司间接全资附属公司北京佰金生物科技有限公司与优环(苏州)生物医药科技有限公司签订策略合作框架协议，据此，北京佰金将透过认购优环生物股权的方式对优环生物进行投资，旨在打造全球领先的环状RNA技术研发平台并借助此平台，深化细胞治疗领域的技术创新。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1370981.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE0009354923.USD","01466","BK4139","BK4505","BK1227","BK4585","BK4588","RNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2584957390","title":"Wave Life Sciences Ltd.盘中异动 股价大跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584957390","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584957390?lang=zh_cn&edition=full","pubTime":"2025-11-19 00:04","pubTimestamp":1763481852,"startTime":"0","endTime":"0","summary":"北京时间2025年11月19日00时04分，Wave Life Sciences Ltd.股票出现波动，股价快速跳水5.03%。Wave Life Sciences Ltd.股票所在的生物技术行业中，整体跌幅为0.38%。Wave Life Sciences Ltd.公司简介：WAVE Life Sciences Ltd 是一家临床阶段的生物技术公司，专注于释放 RNA 药物的广泛潜力，靶向核糖核酸 ，以改变人类健康。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119000412950c86ac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119000412950c86ac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0009354923.USD","BK4139","BK4007","BK4585","RNA","BK4505","WVE","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.atriumtherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0023},{"period":"1month","weight":-0.0424},{"period":"3month","weight":-0.285},{"period":"6month","weight":-0.285},{"period":"1year","weight":-0.285},{"period":"ytd","weight":-0.285}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0948},{"period":"3month","weight":0.0413},{"period":"6month","weight":0.0597},{"period":"1year","weight":0.2669},{"period":"ytd","weight":0.0529}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Atrium Therapeutics, Inc.于2025年9月30日根据特拉华州法律注册成立，是Avidity Biosciences, Inc.的直接全资子公司。该公司是一家生物制药公司，致力于开创向心脏输送RNA疗法的先河，旨在改变心肌病患者个人的护理标准。利用最初在Avidity开发的专有RNA递送平台，该公司将单克隆抗体的组织选择性与寡核苷酸的精确度相结合，以靶向以前无法药物治疗的疾病的遗传驱动因素。Atrium专注于解决影响全球数百万人的基因驱动心肌病，其开发管道包括针对与严重心脏病相关的特定基因驱动因素的项目。在稳健的临床前和积极的临床数据支持下，该公司定位于重新定义精准心脏病学中的治疗范式。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.025613},{"month":2,"riseRate":0.666667,"avgChangeRate":0.084173},{"month":3,"riseRate":0.4,"avgChangeRate":-0.00029},{"month":4,"riseRate":0.4,"avgChangeRate":-0.058331},{"month":5,"riseRate":0.4,"avgChangeRate":-0.018927},{"month":6,"riseRate":0.8,"avgChangeRate":0.113151},{"month":7,"riseRate":0.5,"avgChangeRate":0.027674},{"month":8,"riseRate":0.666667,"avgChangeRate":0.073003},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.048121},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.000506},{"month":11,"riseRate":0.666667,"avgChangeRate":0.096576},{"month":12,"riseRate":0.666667,"avgChangeRate":0.110632}],"exchange":"NASDAQ","name":"Atrium Therapeutics","nameEN":"Atrium Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Atrium Therapeutics(RNA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Atrium Therapeutics(RNA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Atrium Therapeutics,RNA,Atrium Therapeutics股票,Atrium Therapeutics股票老虎,Atrium Therapeutics股票老虎国际,Atrium Therapeutics行情,Atrium Therapeutics股票行情,Atrium Therapeutics股价,Atrium Therapeutics股市,Atrium Therapeutics股票价格,Atrium Therapeutics股票交易,Atrium Therapeutics股票购买,Atrium Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Atrium Therapeutics(RNA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Atrium Therapeutics(RNA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}